Dr Michelle Tempest and George Holden of Candesic, investigate the emerging market and white space in digital clinical trials and discuss how mixing old and new pathways will disrupt the sector and create global investment opportunities
Innovation is for the curious and those who love to experiment. Clinical trials are all about bringing innovation from bench to bedside. Historically, they have been restricted to the confines of physical buildings, headquartered in academic centres and heavily paper based. The result has been several unintended consequences, such as lack of diversity among human sample sets, high costs, and very long timelines. Some 80% of clinical trials fail to meet initial recruitment targets and deadlines1.